Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 318

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Low temperature fused deposition modeling (FDM) 3D printing of thermolabile drugs

Open access
Kollamaram, Gayathri, Croker, Denise M., Walker, Gavin M., Goyanes, Alvaro, Basit, Abdul W., Gaisford, Simon·2018·International Journal of Pharmaceutics

Abstract

ABSTRACT Fused deposition modelling (FDM) is the most commonly investigated 3D printing technology for the manufacture of personalized medicines, however, the high temperatures used in the process limit its wider application. The objective of this study was to print low‐melting and thermolabile drugs by reducing the FDM printing temperature. Two immediate release polymers, Kollidon VA64 and Kollidon 12PF were investigated as potential candidates for low‐temperature FDM printing. Ramipril was used as the model low melting temperature drug (109°C); to the authors’ knowledge this is the lowest melting point drug investigated to date by FDM printing. Filaments loaded with 3% drug were obtained by hot melt extrusion at 70°C and ramipril printlets with a dose equivalent of 8.8mg were printed at 90°C. HPLC analysis confirmed that the drug was stable with no signs of degradation and dissolution studies revealed that drug release from the printlets reached 100% within 20–30min. Variable temperature Raman and solid state nuclear magnetic resonance (SSNMR) spectroscopy techniques were used to evaluate drug stability over the processing temperature range. These data indicated that ramipril did not undergo degradation below its melting point (which is above the processing temperature range: 70–90°C) but it was transformed into the impurity diketopiperazine upon exposure to temperatures higher than its melting point. The use of the excipients Kollidon VA64 and Kollidon 12PF in FDM was further validated by printing with the drug 4‐aminosalicylic acid (4‐ASA), which in previous work was reported to undergo degradation in FDM printing, but here it was found to be stable. This work demonstrates that the selection and use of new excipients can overcome one of the major disadvantages in FDM printing, drug degradation due to thermal heating, making this technology suitable for drugs with lower melting temperatures.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ijpharm.2018.04.055

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 318

Metadata

Authors
Kollamaram, G., Croker, D. M., Walker, G. M., Goyanes, A., Basit, A. W., & Gaisford, S.
Venue
International Journal of Pharmaceutics
Publisher
Elsevier BV
Published
2018-07
Volume
545
Issue
1-2
Pages
144-152
ISSN
0378-5173 (ISSN-L)
OpenAlex
W2800695185
Cited by
318
References
45
FWCI
21.02
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low temperature fused deposition modeling (FDM) 3D printing of thermolabile drugs. https://app.cochat.ai/papers/10.1016/j.ijpharm.2018.04.055
The paper
Kollamaram, G., Croker, D. M., Walker, G. M., Goyanes, A., Basit, A. W., & Gaisford, S. (2018). Low temperature fused deposition modeling (FDM) 3D printing of thermolabile drugs. International Journal of Pharmaceutics. https://doi.org/10.1016/j.ijpharm.2018.04.055

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.